The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...

A new preprint study suggests that Moderna’s COVID-19 vaccine may be significantly more effective against symptomatic disease from the delta variant compared to Pfizer-BioNTech’s vaccine, while the ...

Moderna has filed a lawsuit against Pfizer and its German partner BioNTech for allegedly copying their COVID-19 vaccine. On Friday, Moderna issued a news release accusing Pfizer of infringing several ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...